ABBVIE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 163.8 USD | -1.28% |
|
-4.27% | +5.72% |
| Jul. 03 | AbbVie cuts 2024 profit forecast | RE |
| Jul. 01 | Merus Names New Chief Medical Officer | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
Pharmaceuticals
Calendar
2024-07-14
- Détachement de
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
163.8
USD
Average target price
183.2
USD
Spread / Average Target
+11.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.72% | 289B | |
| +54.07% | 809B | |
| +38.95% | 621B | |
| -7.05% | 351B | |
| +15.44% | 319B | |
| +14.21% | 238B | |
| -0.45% | 221B | |
| +14.58% | 218B | |
| +7.42% | 166B | |
| -3.79% | 157B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- AbbVie Keeps Quarterly Dividend at $1.55 per Share, Payable Aug. 15 to Shareholders of Record July 15
